Should pharmacometrics be training the next R&D president?

We continue to train pharmacometric scientists primarily in methodology. The lack of training in business and drug development concepts, however, is preventing pharmacometricians from becoming high-level decision makers. The more recent growth of opportunities in pharmacometrics is propelled by applications within both companies and regulatory agencies. However, these applications themselves may not lead to sustained growth of opportunities. How can we prepare pharmacometricians to fundamentally re-engineer the drug development paradigm?